Skip to Main Content
Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2020, Issue 1
December 4 2020
Issue Cover
In this Issue

Table of Contents

Ham-Wasserman Lecture

Therapeutic development and current uses of BCL-2 inhibition
Andrew W. Roberts
View Articletitled, Therapeutic development and current uses of BCL-2 inhibition

A Map for the Changing Landscape of CLL

Approaches for relapsed CLL after chemotherapy-free frontline regimens
Lindsey E. Roeker,Anthony R. Mato
View Articletitled, Approaches for relapsed CLL after chemotherapy-free frontline regimens
Evidence-Based Minireview: Treatment of relapsed chronic lymphocytic leukemia after venetoclax
Evidence-Based Minireview
Meghan C. Thompson,Anthony R. Mato
View Articletitled, Evidence-Based Minireview: Treatment of relapsed chronic lymphocytic leukemia after venetoclax
Chemotherapy-free frontline therapy for CLL: is it worth it?
Joanna M. Rhodes,Jacqueline C. Barrientos
View Articletitled, Chemotherapy-free frontline therapy for CLL: is it worth it?
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy
Carol Moreno
View Articletitled, Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy

Acute Myeloid Leukemia—So Many Treatment Options; How Do You Decide?

Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
Evan C. Chen,Jacqueline S. Garcia
View Articletitled, Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia
Alison R. Walker
View Articletitled, How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia
Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop
Eunice S. Wang,Jeffrey Baron
View Articletitled, Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop

Advances in the Laboratory Assessment of Hemostatic and Thrombotic Disorders

“TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry
Rita Selby
View Articletitled, “TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry
Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders
Michele P Lambert
View Articletitled, Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders
Evidence-Based Minireview: Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura
Evidence-Based Minireview
Ang Li,Johanna A. Kremer Hovinga
View Articletitled, Evidence-Based Minireview: Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura

Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?

Can we use epigenetics to prime chemoresistant lymphomas?
Jennifer E. Amengual
View Articletitled, Can we use epigenetics to prime chemoresistant lymphomas?
Harnessing lymphoma epigenetics to improve therapies (article not eligible for CME credit)
Haopeng Yang,Michael R. Green
View Articletitled, Harnessing lymphoma epigenetics to improve therapies (article not eligible for CME credit)
Novel targets in aggressive lymphoma
Kami Maddocks
View Articletitled, Novel targets in aggressive lymphoma

Beyond the Marrow: Major Nonhematologic Complications of Inherited Bone Marrow Failure Syndromes

Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes
Carmem Bonfim
View Articletitled, Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes
Extrahematopoietic manifestations of the short telomere syndromes
Kristen E. Schratz
View Articletitled, Extrahematopoietic manifestations of the short telomere syndromes

Caring for Patients with Acute Leukemia in Community Hospitals: Who, What, and When to Refer?

Optimizing management of acute leukemia in community centers and when to refer
Anand P. Jillella,Jorge E. Cortes,Vamsi K. Kota
View Articletitled, Optimizing management of acute leukemia in community centers and when to refer
Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings
Anna B. Halpern,Roland B. Walter
View Articletitled, Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings
Updates in infection risk and management in acute leukemia
C. Logan,D. Koura,R. Taplitz
View Articletitled, Updates in infection risk and management in acute leukemia

Challenging Situations for Patients with Aggressive Lymphomas

Approaches to aggressive B-cell lymphomas in less fit patients
Nancy L. Bartlett
View Articletitled, Approache<s>s</s> to aggressive B-cell lymphomas in less fit patients
Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas
Oreofe O. Odejide
View Articletitled, Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas
Strategies for aggressive T-cell lymphoma: divide and conquer
Lauren C. Pinter-Brown
View Articletitled, Strategies for aggressive T-cell lymphoma: divide and conquer

Chronic Transfusion Support: Challenging Cases

Challenges in chronic transfusion for patients with thalassemia
Ashutosh Lal
View Articletitled, Challenges in chronic transfusion for patients with thalassemia
Outpatient transfusions for myelodysplastic syndromes
Erica M. Wood,Zoe K. McQuilten
View Articletitled, Outpatient transfusions for myelodysplastic syndromes
Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life
Jennifer Webb
View Articletitled, Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life

Diagnostic and Prognostic Models in VTE Management: Ready for Prime time?

Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism?
Wee-Shian Chan
View Articletitled, Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism?
When I treat a patient with acute pulmonary embolism at home
Frederikus A. Klok,Menno V. Huisman
View Articletitled, When I treat a patient with acute pulmonary embolism at home
Evidence-Based Minireview: Advanced therapies and extracorporeal membrane oxygenation for the management of high-risk pulmonary embolism
Evidence-Based Minireview
Radhika Gangaraju,Frederikus A. Klok
View Articletitled, Evidence-Based Minireview: Advanced therapies and extracorporeal membrane oxygenation for the management of high-risk pulmonary embolism
Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?
Fionnuala Ní Áinle,Barry Kevane
View Articletitled, Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?

Genetic Testing for Heritable Hematologic Disorders 101

Informed consent for genetic testing in hematology
Jonathan M. Marron
View Articletitled, Informed consent for genetic testing in hematology
Identifying potential germline variants from sequencing hematopoietic malignancies
Ira L. Kraft,Lucy A. Godley
View Articletitled, Identifying potential germline variants from sequencing hematopoietic malignancies

Handling Challenging Questions in the Management of CML

First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
Vivian G. Oehler
View Articletitled, First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
How to manage CML patients with comorbidities
Jorge Cortes
View Articletitled, How to manage CML patients with comorbidities
Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
Delphine Rea
View Articletitled, Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?

Immunotherapy in Multiple Myeloma

Sequencing multiple myeloma therapies with and after antibody therapies
Niels W. C. J. van de Donk
View Articletitled, Sequencing multiple myeloma therapies with and after antibody therapies
Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibody–based treatment?
Evidence-Based Minireview
Charlotte L. B. M. Korst,Niels W. C. J. van de Donk
View Articletitled, Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibody–based treatment?
Bispecifics, trispecifics, and other novel immune treatments in myeloma
Guido Lancman,Joshua Richter,Ajai Chari
View Articletitled, Bispecifics, trispecifics, and other novel immune treatments in myeloma
Future of CAR T cells in multiple myeloma
Kitsada Wudhikarn,Sham Mailankody,Eric L. Smith
View Articletitled, Future of CAR T cells in multiple myeloma

Improving Symptom Control for Children with Hematological Malignancies

Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies
Lillian Sung,Tamara P. Miller,Robert Phillips
View Articletitled, Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies

Indolent Lymphomas: Answers to Smoldering Questions

How do I sequence therapy for follicular lymphoma?
Gilles Salles
View Articletitled, How do I sequence therapy for follicular lymphoma?
How do we sequence therapy for marginal zone lymphomas?
Alessandro Broccoli,Pier Luigi Zinzani
View Articletitled, How do we sequence therapy for marginal zone lymphomas?
Transformed lymphoma: what should I do now?
Sonali Smith
View Articletitled, Transformed lymphoma: what should I do now?

Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis When Treating Nonmalignant Hematologic Disorders

Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs
Elissa R. Engel,Jolan E. Walter
View Articletitled, Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases
Luis Malpica,Stephan Moll
View Articletitled, Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases
Preventing infections in children and adults with asplenia
Grace M. Lee
View Articletitled, Preventing infections in children and adults with asplenia

Managing Toxicities of Targeted Therapies in CLL

Managing toxicities of Bruton tyrosine kinase inhibitors
Andrew Lipsky,Nicole Lamanna
View Articletitled, Managing toxicities of Bruton tyrosine kinase inhibitors
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors
Ashley Hanlon,Danielle M. Brander
View Articletitled, Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia
Kirsten Fischer,Othman Al-Sawaf,Michael Hallek
View Articletitled, Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia

Monoclonal Gammopathies of Determined Significance

Management of AL amyloidosis in 2020
Giovanni Palladini,Paolo Milani,Giampaolo Merlini
View Articletitled, Management of AL amyloidosis in 2020
Management of Waldenström macroglobulinemia in 2020
Jorge J. Castillo,Steven P. Treon
View Articletitled, Management of Waldenström macroglobulinemia in 2020
Monoclonal gammopathies of clinical significance
Angela Dispenzieri
View Articletitled, Monoclonal gammopathies of clinical significance

More Anxiety-Provoking Hematology Consults

A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact
Ari Zimran,Rosa Ruchlemer,Shoshana Revel-Vilk
View Articletitled, A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact
Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease
Kenneth McClain
View Articletitled, Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease
Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP
Michael Linenberger,Kleber Y. Fertrin
View Articletitled, Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP

Myelodysplastic Syndromes: What We Have and What We Want

Existing agents, novel agents, or transplantation for high-risk MDS
Bart L. Scott
View Articletitled, Existing agents, novel agents, or transplantation for high-risk MDS
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map
Anne Sophie Kubasch,Uwe Platzbecker
View Articletitled, Patient stratification in myelodysplastic syndromes: how a puzzle may become a map
Therapy for lower-risk MDS
Hetty E. Carraway,Caner Saygin
View Articletitled, Therapy for lower-risk MDS

Myeloproliferative Disorders: Too Many Cells, Too Few Therapies

Applied genomics in MPN presentation
Alison R. Moliterno,Hannah Kaizer
View Articletitled, Applied genomics in MPN presentation
Genomics of MPN progression
Anand A. Patel,Olatoyosi Odenike
View Articletitled, Genomics of MPN progression
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
Mrinal M. Patnaik,Terra L. Lasho
View Articletitled, Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review
Evidence-Based Minireview
Mrinal M. Patnaik,Terra Lasho
View Articletitled, Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review

Out of Balance: Anemias Due to Disordered Iron Homeostasis

Inherited microcytic anemias
Maria Domenica Cappellini,Roberta Russo,Immacolata Andolfo,Achille Iolascon
View Articletitled, Inherited microcytic anemias
Global look at nutritional and functional iron deficiency in infancy
Michael B. Zimmermann
View Articletitled, Global look at nutritional and functional iron deficiency in infancy
Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?
Kleber Yotsumoto Fertrin
View Articletitled, Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?

Pediatric Hematological Malignancies: CARs for Kids

Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma
Emily M. Hsieh,Rayne H. Rouce
View Articletitled, Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma
CAR T cells for other pediatric non–B-cell hematologic malignancies
Adam J. Lamble,Rebecca Gardner
View Articletitled, CAR T cells for other pediatric non–B-cell hematologic malignancies
CAR T cells vs allogeneic HSCT for poor-risk ALL
Caroline Diorio,Shannon L. Maude
View Articletitled, CAR T cells vs allogeneic HSCT for poor-risk ALL
Evidence-Based Minireview: What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?
Evidence-Based Minireview
Aimee C. Talleur,Shannon L. Maude
View Articletitled, Evidence-Based Minireview: What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?

Platelet Transfusions for Hematology/Oncology Patients

Does ABO and RhD matching matter for platelet transfusion?
Nancy M. Dunbar
View Articletitled, Does ABO and RhD matching matter for platelet transfusion?
How well do platelets prevent bleeding?
Darrell J. Triulzi
View Articletitled, How well do platelets prevent bleeding?
Evidence-Based Minireview: The use of premedications for platelet transfusions in pediatric patients
Evidence-Based Minireview
Meghan McCormick,Darrell Triulzi
View Articletitled, Evidence-Based Minireview: The use of premedications for platelet transfusions in pediatric patients
Platelet transfusion refractoriness: how do I diagnose and manage?
Claudia S. Cohn
View Articletitled, Platelet transfusion refractoriness: how do I diagnose and manage?

Selected Hemostasis and Thrombosis Topics in Women

Management of heavy menstrual bleeding on anticoagulation
Bethany Samuelson Bannow
View Articletitled, Management of heavy menstrual bleeding on anticoagulation
Evidence-Based Minireview: Abnormal uterine bleeding in users of rivaroxaban and apixaban
Evidence-Based Minireview
Amanda E. Jacobson-Kelly,Bethany T. Samuelson Bannow
View Articletitled, Evidence-Based Minireview: Abnormal uterine bleeding in users of rivaroxaban and apixaban
Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management
Claire McLintock
View Articletitled, Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management
Women and bleeding disorders: diagnostic challenges
Paula D. James
View Articletitled, Women and bleeding disorders: diagnostic challenges

The Brain and Pain in Sickle Cell Disease

Neuropathic pain in sickle cell disease: measurement and management
Alexander Glaros,Amanda M. Brandow
View Articletitled, Neuropathic pain in sickle cell disease: measurement and management
Optimizing the management of chronic pain in sickle cell disease
Ifeyinwa Osunkwo,Hazel F. O'Connor,Elna Saah
View Articletitled, Optimizing the management of chronic pain in sickle cell disease

The Emerging Role of Targeted Therapies and Cell Therapy in Transplant

Next-generation cell therapies: the emerging role of CAR-NK cells
Rafet Basar,May Daher,Katayoun Rezvani
View Articletitled, Next-generation cell therapies: the emerging role of CAR-NK cells
Practical aspects of building a new immunotherapy program: the future of cell therapy
Jesús G. Berdeja
View Articletitled, Practical aspects of building a new immunotherapy program: the future of cell therapy

Understanding How to Manipulate the Immune System in Immunotherapy for Lymphoma

Fundamentals of immunology for understanding immunotherapy for lymphoma
Stephen M. Ansell
View Articletitled, Fundamentals of immunology for understanding immunotherapy for lymphoma
Immunotherapy with cells (article not eligible for CME credit)
Elise A. Chong,David L. Porter
View Articletitled, Immunotherapy with cells (article not eligible for CME credit)
Immunotherapy with drugs
Yun Choi,Catherine S. Diefenbach
View Articletitled, Immunotherapy with drugs

Updates on the Role of Nonanticoagulant Interventions in Venous Thromboembolism

Role of venous stenting for venous thromboembolism
Karen Breen
View Articletitled, Role of venous stenting for venous thromboembolism
Thrombolytic therapy in acute venous thromboembolism
Thita Chiasakul,Kenneth A. Bauer
View Articletitled, Thrombolytic therapy in acute venous thromboembolism
Inferior vena cava filters: a framework for evidence-based use
Amar H. Kelkar,Anita Rajasekhar
View Articletitled, Inferior vena cava filters: a framework for evidence-based use
Evidence-Based Minireview: Do prophylactic inferior vena cava filters in trauma patients reduce the risk of mortality or pulmonary embolism?
Evidence-Based Minireview
Amar H. Kelkar,Anita Rajasekhar
View Articletitled, Evidence-Based Minireview: Do prophylactic inferior vena cava filters in trauma patients reduce the risk of mortality or pulmonary embolism?

What Hematologists Need to Know About Giving and Stopping Aspirin

Professional illustration by Patrick Lane, ScEYEnce Studios

Does aspirin prevent venous thromboembolism?
Robert Diep,David Garcia
View Articletitled, Does aspirin prevent venous thromboembolism?
Combining antiplatelet and anticoagulant therapy in cardiovascular disease
Geoffrey D. Barnes
View Articletitled, Combining antiplatelet and anticoagulant therapy in cardiovascular disease

Yin and Yang of Autoimmunity and Immunodeficiencies in Hematology

Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
Emma C. Morris
View Articletitled, Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation
Roshini S. Abraham
View Articletitled, How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation
Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)
Markus G. Seidel
View Articletitled, Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)

Erratum

Sanz GF. In MDS, is higher risk higher reward? Hematology Am Soc Hematol Educ Program. 2019;2019:381-390.
View Articletitled, Sanz GF. In MDS, is higher risk higher reward? <em>Hematology Am Soc Hematol Educ Program.</em> 2019;2019:381-390.
All Issues
Targeted medical therapies for vascular anomalies
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma
Transplant in ALL: who, when, and how?
Ph− ALL: immunotherapy in upfront treatment
Ph+ ALL: new approaches for upfront therapy
  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal